TY - JOUR T1 - Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 1167 LP - 1172 DO - 10.3899/jrheum.171006 VL - 45 IS - 8 AU - Vanessa Cecchin AU - Maria Elisabetta Zannin AU - Daniele Ferrari AU - Irene Pontikaki AU - Elisabetta Miserocchi AU - Maria P. Paroli AU - Claudia Bracaglia AU - Denise Pires Marafon AU - Serena Pastore AU - Fulvio Parentin AU - Gabriele Simonini AU - Cinzia De Libero AU - Fernanda Falcini AU - Antonella Petaccia AU - Giovanni Filocamo AU - Riccardo De Marco AU - Francesco La Torre AU - Silvana Guerriero AU - Silvana Martino AU - Francesco Comacchio AU - Valentina Muratore AU - Giorgia Martini AU - Fabio Vittadello AU - Francesco Zulian Y1 - 2018/08/01 UR - http://www.jrheum.org/content/45/8/1167.abstract N2 - Objective. Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years.Methods. Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for ≥ 2 years were analyzed by descriptive statistics.Results. Up to December 2014, 154 patients with ≥ 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for > 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p < 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.Conclusion. At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis. ER -